Page 2,482«..1020..2,4812,4822,4832,484..2,4902,500..»

“Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury” – Stephen Huhn, MD – Video

Posted: December 18, 2012 at 1:42 pm


"Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury" - Stephen Huhn, MD
Dr. Huhn, who is Vice President, Head of the CNS Program at Stem Cells, Inc., provides an update on the company #39;s clinical trial.From:unite2fightparalysisViews:0 0ratingsTime:23:03More inNonprofits Activism

Go here to see the original:
"Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury" - Stephen Huhn, MD - Video

Posted in Stem Cells | Comments Off on “Study of Human Neural Stem Cells in Thoracic Spinal Cord Injury” – Stephen Huhn, MD – Video

In the Flesh: The Embedded Dangers of Untested Stem Cell Cosmetics

Posted: December 18, 2012 at 1:40 pm

When cosmetic surgeon Allan Wu first heard the woman's complaint, he wondered if she was imagining things or making it up. A resident of Los Angeles in her late sixties, she explained that she could not open her right eye without considerable pain and that every time she forced it open, she heard a strange clicka sharp sound, like a tiny castanet snapping shut. After examining her in person at The Morrow Institute in Rancho Mirage, Calif., Wu could see that something was wrong: Her eyelid drooped stubbornly, and the area around her eye was somewhat swollen. Six and a half hours of surgery later, he and his colleagues had dug out small chunks of bone from the woman's eyelid and tissue surrounding her eye, which was scratched but largely intact. The clicks she heard were the bone fragments grinding against one another.

About three months earlier the woman had opted for a relatively new kind of cosmetic procedure at a different clinic in Beverly Hillsa face-lift that made use of her own adult stem cells. First, cosmetic surgeons had removed some the woman's abdominal fat with liposuction and isolated the adult stem cells withina family of cells that can make many copies of themselves in an immature state and can develop into several different kinds of mature tissue. In this case the doctors extracted mesenchymal stem cellswhich can turn into bone, cartilage or fat, among other tissuesand injected those cells back into her face, especially around her eyes. The procedure cost her more than $20,000, Wu recollects. Such face-lifts supposedly rejuvenate the skin because stem cells turn into brand-new tissue and release chemicals that help heal aging cells and stimulate nearby cells to proliferate.

During the face-lift her clinicians had also injected some dermal filler, which plastic surgeons have safely used for more than 20 years to reduce the appearance of wrinkles. The principal component of such fillers is calcium hydroxylapatite, a mineral with which cell biologists encourage mesenchymal stem cells to turn into bonea fact that escaped the woman's clinicians. Wu thinks this unanticipated interaction explains her predicament. He successfully removed the pieces of bone from her eyelid in 2009 and says she is doing well today, but some living stem cells may linger in her face. These cells could turn into bone or other out-of-place tissues once again.

Dozens, perhaps hundreds, of clinics across the country offer a variety of similar, untested stem cell treatments for both cosmetic and medical purposes. Costing between $3,000 and $30,000, the treatments promise to alleviate everything from wrinkles to joint pain to autism. The U.S. Food and Drug Administration (FDA) has not approved any of these treatments and, with a limited budget, is struggling to keep track of all the unapproved therapies on the market. At the same time, pills, oils, creams and moisturizers that allegedly contain the right combination of ingredients to mobilize the body's resident stem cells, or contain chemicals extracted from the stem cells in plants and animals, are popping up in pharmacies and online. There's Stem Cell 100, for example, MEGA STEM and Apple Stem Cell Cloud Cream. Few of these cosmetics have been properly tested in published experiments, yet the companies that manufacture them say they may heal damaged organs, slow or reverse natural aging, restore youthful energy and revitalize the skin. Whether such cosmetics may also produce unintended and potentially harmful effects remains largely unexamined. The increasing number of untested and unauthorized stem cell treatments threaten both people who buy them and researchers hoping to conduct clinical trials for promising stem cell medicine.

When is a skin cream a drug? So far, the FDA has only approved one stem cell treatment: a transplant of bone marrow stem cells for people with the blood cancer leukemia. Among the increasing number of unapproved stem cell treatments, some clearly violate the FDA's regulations whereas others may technically be legal without its approval. In July 2012, for example, the U.S. District Court upheld an injunction brought by the FDA against Colorado-based Regenerative Sciences to regulate just one of the company's several stem cell treatments for various joint injuries as an "unapproved biological drug product." The decision hinged on what constitutes "minimal manipulation" of cells in the lab before they are injected into patients. In the treatment that the FDA won the right to regulate, stem cells are grown and modified in the lab for several weeks before they are returned to patients; in Regenerative Sciences's other treatments, patients' stem cells are extracted and injected within a day or two. Regenerative Sciences now offers the legally problematic treatment at a Cayman Island facility.

Many stem cell cosmetics reside in a legal gray area. Unlike drugs and "biologics" made from living cells and tissues, cosmetics do not require premarket approval from the FDA. But stem cell cosmetics often satisfy the FDA's definitions for both cosmetics and drugs. In September 2012 the FDA posted a letter on its Web site warning Lancme, a division of L'Oral, that the way it describes its Genifique skin care products qualify the creams and serums as unapproved drugs: they are supposed to "boost the activity of genes," for example, and "improve the condition of stem cells." Other times the difference between needing or not needing FDA approval comes down to linguistic nuancethe difference between claiming that a product does something or appears to do something.

Personal Cell Sciences, in Eatontown, N.J., sells some of the more sophisticated stem cellbased cosmetics: an eye cream, moisturizer and serum infused with chemicals derived from a consumer's own stem cells. According to its website and marketing materials, these products help "make skin more supple and radiant," "reduce the appearance of fine lines and wrinkles around the eyes and lips," "improve cellular renewal" and "stimulate cell turnover for renewed texture and tone." In exchange for $3,000, Personal Cell Sciences will arrange for a participating physician to vacuum about 60 cubic centimeters (one quarter cup) of a customer's fat from beneath his or her skin and ship it on ice to American CryoStem Corp. in Red Bank, N.J., where laboratory technicians isolate and grow the customer's mesenchymal stem cells to around 30 million strong. Half these cells are frozen for storage; from the other half, technicians harvest hundreds of different kinds of exuded growth factors and cytokinesmolecules that help heal damaged cells and encourage cells to divide, among other functions. These molecules are mixed with many other ingredientsincluding green tea extract, caffeine and vitaminsto create the company's various "U Autologous" skin care products, which are then sold back to the consumer for between $400 and $800. When the customer wants a refill, technicians thaw some of the frozen cells, collect more cytokines and produce new bottles of cream.

In an unpublished safety trial sponsored by Personal Cell Sciences, Frederic Stern of the Stern Center for Aesthetic Surgery in Bellevue, Wash., and his colleagues monitored 19 patients for eight weeks as they used the U Autologous products on the left sides of their faces. A computer program meant to objectively analyze photos of the volunteers' faces measured an average of 25.6 percent reduction in the volume of wrinkles on the treated side of the face. Analysis of tissue biopsies revealed increased levels of the protein elastin, which helps keep skin taut, and no signs of unusual or cancerous cell growth.

Only skin deep? Supposedly, the primary active ingredients in the U Autologous skin care products are the hundreds of different kinds of cytokines they contain. Cytokines are a large and diverse family of proteins that cells release to communicate with and influence one another. Cytokines can stimulate cell division or halt it; they can suppress the immune system or provoke it; they can also change a cell's shape, modulate its metabolism and force it to migrate from one location to another like a cowboy corralling cattle. Researchers have only named and characterized some of the many cytokines that stem cells secrete. Some of these molecules certainly help repair damaged cells and promote cell survival. Others seem to be involved in the development of tumors. In fact, some recent evidence suggests that the cytokines released by mesenchymal stem cells can trigger tumors by accelerating the growth of dormant cancer cells. Personal Cell Sciences does not pick and choose among the cytokines exuded by its customers' stem cellsinstead, it dumps them all into its skin care products.

Based on the available evidence so far, topical creams containing cytokines from stem cells pose far less risk of cancer than living stem cells injected beneath the skin. But scientists do not yet know enough about stem cell cytokines to reliably predict everything they will do when rubbed into the skin; they could interact with healthy skin cells in a completely unexpected way, just as the unintended interplay between calcium hydroxylapatite and stem cells produced bones in the Los Angeles woman's eye. Stern acknowledges that unusual tissue growth is a concern for any treatment based on stem cells and the chemicals they release. "Down the line, we want to continue watching that," he says. Unlike many other clinics, he and his colleagues have been keeping tabs on their patients through regular follow-ups. John Arnone, CEO of American CryoStem and founder of Personal Cell Sciences, says the fact that U Autologous skin care products contain such a diversity of cytokines does not bother him: "I've seen worse things out there. I've been putting this formulation for almost a year on myself prior to the study. I'm the best guinea pig here."

Follow this link:
In the Flesh: The Embedded Dangers of Untested Stem Cell Cosmetics

Posted in Cell Medicine | Comments Off on In the Flesh: The Embedded Dangers of Untested Stem Cell Cosmetics

Stem cell therapy True or fiction Dr. Ahmed korie alexandria university – Video

Posted: December 18, 2012 at 1:40 pm


Stem cell therapy True or fiction Dr. Ahmed korie alexandria university
Stem cell therapy True or fiction Dr. Ahmed korie alexandria universityFrom:mansvuViews:2 0ratingsTime:29:49More inEducation

Read more:
Stem cell therapy True or fiction Dr. Ahmed korie alexandria university - Video

Posted in Stem Cell Therapy | Comments Off on Stem cell therapy True or fiction Dr. Ahmed korie alexandria university – Video

Stem Cell’s explained part 1 on The Susana Kennedy Show on 2oceansvibe – Video

Posted: December 18, 2012 at 1:40 pm


Stem Cell #39;s explained part 1 on The Susana Kennedy Show on 2oceansvibe
My ever increasing curiosity with the possibilities of Stem Cell therapy recently led me to meeting up with Dr. Duncan Carmichael from The Anti-Aging Clinic in Cape town, we chatted about what stem cell #39;s are, what some of the possibilities are and more, this is part one of a series of interviews I will be releasing over the next few weeks, demystifying the myths and revealing the incredible possibilities that are actually already available to you all right now. Enjoy!From:Susana KennedyViews:2 0ratingsTime:08:32More inScience Technology

Read this article:
Stem Cell's explained part 1 on The Susana Kennedy Show on 2oceansvibe - Video

Posted in Stem Cell Therapy | Comments Off on Stem Cell’s explained part 1 on The Susana Kennedy Show on 2oceansvibe – Video

BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process

Posted: December 18, 2012 at 1:40 pm

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate. The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, significantly increasing its production capabilities by using a single clean room for multiple patients, reducing costs and time. The project is supported by a grant awarded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF).

Under the terms of the agreement, the companies will develop a commercially viable, safe, reliable, and cost-effective bioreactor for scale-up of BrainStorms NurOwn stem cell therapy, using Octanes Automated Cell & Tissue Engineering System (ACTES) technology. The CIIRDF funding award was approved for a period of three years.

Octane is the ideal partner for us, since they have a particular expertise in developing automated production processes for mesenchymal cell therapy technologies, commented Dr. Adrian Harel, BrainStorms CEO. We are anxious to move ahead with this project, in order to be in a position to provide NurOwn as quickly as possible, and to as many patients as possible, in the near future.

The opportunity to work with BrainStorm on scaling-up the NurOwn production process is a particularly meaningful one, given the urgency of its target population, said Dr. Tim Smith, Octanes CEO. We are confident that our combined knowledge base and commitment to the project will help advance their product significantly closer to clinical use.

BrainStorm is currently conducting a Phase I/II clinical trial in ALS patients at the Hadassah Medical Center in Jerusalem and is planning to expand its clinical development in the USA, pending FDA approval. Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.

About BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

About Octane Biotech

Octane develops innovative bioreactor-based systems to meet the production challenges inherent in the progressive scale-up of manual cell culture protocols. The companys unique Automated Cell & Tissue Engineering System (ACTES) solution integrates state-of-the-art bioreactors, biosensors and bioprocessing to enable routine GMP production of cell-based products for clinical therapeutics. Octane Biotech Inc. is one of three affiliated companies within the Octane Medical Group. For more information, visit the companys website at http://www.octaneco.com.

Continue reading here:
BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process

Posted in Cell Therapy | Comments Off on BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process

California Editorial Unamity: Stem Cell Agency Needs Revamp

Posted: December 18, 2012 at 12:40 pm

With the addition of another editorial
this week, reaction among California newspapers so far has been
unanimous that the $3 billion California stem cell agency should heed
the sweeping recommendations of the prestigious Institute of
Medicine.

The Riverside Press-Enterprise added its voice yesterday, declaring,

“Good intentions do not justify poor
practice.”

Like others, the newspaper said that
the agency “needs to revamp its governance structure to avoid
potential conflicts of interest and boost public confidence in the
agency.”
The Riverside paper focused on the conflicts of interest at the organization, which has seen about
90 percent of its funding go to institutions with ties to directors, but also supported other recommendations, including elimination of the dual executive arrangement at the research effort. 
The editorial said,

“An agency spending Californians’
money has no business being cavalier about good government practice
and ethical safeguards — no matter how promising the potential
therapies might be. The stem-cell institute is not a private fiefdom,
but a taxpayer-supported undertaking. Yet many on the stem-cell
institute’s board objected this month to the report’s
recommendations.

“The agency also said that Prop. 71’s
provisions mean that enacting many of the proposed fixes would
require either a supermajority vote of the Legislature or another
ballot measure. That prospect should warn Californians about the
dangers of voting for complex, costly, politically driven initiatives
that have little to do with fundamental state duties.

“Still, the stem-cell agency cannot
just sit on these recommendations without damaging its credibility.
The search for medical breakthroughs does not justify ignoring vital
safeguards for spending taxpayer dollars.”

For a look at other editorials, see here and here.Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/70xi8-waM7k/california-editorial-unamity-stem-cell.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Editorial Unamity: Stem Cell Agency Needs Revamp

In the Flesh: The Embedded Dangers of Untested Stem Cell Cosmetics

Posted: December 18, 2012 at 5:46 am

Posted in Cell Medicine | Comments Off on In the Flesh: The Embedded Dangers of Untested Stem Cell Cosmetics

Myriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference

Posted: December 18, 2012 at 5:45 am

SALT LAKE CITY, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 2013 J.P. Morgan Annual Healthcare Conference, at 9:30 a.m. Pacific Time on Monday, January 7, 2013. The conference is being held at the Westin St. Francis in San Francisco, California.

The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at http://www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

Visit link:
Myriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference

Posted in Genetics | Comments Off on Myriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference

Stem cells and Diabetes – Video

Posted: December 17, 2012 at 9:41 am


Stem cells and Diabetes
Song- I remember, by Deadmau5 KaskadeFrom:mastercheef524Views:0 0ratingsTime:01:06More inPeople Blogs

Original post:
Stem cells and Diabetes - Video

Posted in Stem Cell Videos | Comments Off on Stem cells and Diabetes – Video

Seattle Genetics to test possible new Adcetris use

Posted: December 16, 2012 at 10:41 pm

Seattle Genetics Inc. plans to proceed with a late-stage study of a possible additional use for its lymphatic cancer treatment Adcetris after releasing results from a small, early-stage test.

The Bothell, Wash., company said Sunday 23 of 26 patients with an aggressive form of non-Hodgkin lymphoma who received Adcetris combined with chemotherapy achieved complete remission, which means they had no trace of the cancer after the treatment was completed.

CEO Clay B. Siegall said in a statement the data offers a "strong rationale" for late-stage testing that will compare Adcetris combined with chemotherapy to the standard chemotherapy treatment for the disease. The company plans to start the trial by early next year.

Seattle Genetics announced the results at the American Society of Hematology's annual meeting in Atlanta.

Adcetris is Seattle Genetics' only marketed product. It is already approved to treat two types of lymphoma. The company also is seeking approval to market the drug as a treatment for mycosis fungoides, a type of non-Hodgkin lymphoma that starts in the skin.

Last month, the Food and Drug Administration gave the treatment orphan drug status for that indication. That means that if Adcetris is approved as a treatment for that disease, the FDA won't approve similar products for seven years.

Orphan drug status is given to treatments for disease that affect fewer than 200,000 Americans.

Shares of Seattle Genetics fell 14 cents to $25.40 in Monday morning trading, while the Nasdaq exchange rose less than 1 percent. The company's shares are still up about 52 percent since closing 2011 at $16.72.

Read the original:
Seattle Genetics to test possible new Adcetris use

Posted in Genetics | Comments Off on Seattle Genetics to test possible new Adcetris use

Page 2,482«..1020..2,4812,4822,4832,484..2,4902,500..»